Sonnet biotherapeutics announces positive results from a preclinical combination study of son-1010 with anti-pd1 checkpoint inhibition

Tumor volume growth inhibition improvements observed with the combination of son-1010 (il12-fhab) and a commercially available anti-pd1 antibody combination of son-1010 with anti-pd1 increased survival rate these data will guide future combination study designs with son-1010 and checkpoint inhibitors princeton, nj / accesswire / june 9, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced data from a preclinical combination study of son-1010 with a commercially available anti-pd1 compound. these results suggest that dosing of son-1010 (il12- fhab) in combination with anti-pd1 demonstrated strong efficacy in the b16f10 mouse melanoma model, historically known as an immunologically insensitive model to anti-pd1.
SONN Ratings Summary
SONN Quant Ranking